Clinical Trial Update: CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a CD19 and CD20 bispecific CAR T cell therapy for relapsed or refractory B-cell hematologic malignancies; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Lymphoblastic Lymphoma

Drugs mentioned

• CD19-CD20 bispecific CAR T cells (CD19/CD20 bispecific chimeric antigen receptor T cells)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1, Phase 2 | Status: RECRUITING